Mari Energies Limited (PSX:MARI)

CTI BioPharma Income Statement

Financials in millions PKR. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	141,486	159,731	128,221	83,135	63,703
Revenue Growth (YoY)	-11.42%	24.57%	54.23%	30.50%	0.76%
Cost of Revenue	41,113	34,834	26,297	16,882	14,685
Gross Profit	100,373	124,897	101,925	66,253	49,018
Selling, General & Admin	-	1,070	814.98	520.86	354.48
Other Operating Expenses	4,394	9,371	7,884	4,553	3,670
Operating Expenses	19,256	23,365	24,716	16,005	8,568
Operating Income	81,117	101,532	77,209	50,248	40,450
Interest Expense	-3,489	-70.28	-34.58	-	-
Interest & Investment Income	-	9,735	4,519	2,541	3,941
Earnings From Equity Investments	291.21	-284.23	-390.02	-2,613	-47.98
Currency Exchange Gain (Loss)	-	-526.26	4,556	1,942	-409.8
Other Non Operating Income (Expenses)	10,674	-23.73	-12.34	-1.3	-1.38
EBT Excluding Unusual Items	88,593	110,363	85,847	52,116	43,931
Pretax Income	88,593	110,363	85,847	52,116	43,931
Income Tax Expense	23,212	33,075	29,718	19,053	12,486
Earnings From Continuing Operations	65,381	77,288	56,129	33,063	31,445
Minority Interest in Earnings	-12.28	-	-	-	-
Net Income	65,369	77,288	56,129	33,063	31,445
Net Income to Common	65,369	77,288	56,129	33,063	31,445
Net Income Growth	-15.42%	37.70%	69.76%	5.15%	3.74%
Shares Outstanding (Basic)	1,201	1,201	1,201	1,201	1,201
Shares Outstanding (Diluted)	1,201	1,201	1,201	1,201	1,201
Shares Change (YoY)	-0.01%	-	-	-	-
EPS (Basic)	54.45	64.37	46.75	27.54	26.19
EPS (Diluted)	54.45	64.37	46.75	27.54	26.19
EPS Growth	-15.42%	37.70%	69.76%	5.15%	3.74%
Free Cash Flow	26,908	51,789	13,949	9,942	3,778
Free Cash Flow Per Share	22.41	43.13	11.62	8.28	3.15
Dividend Per Share	-	25.778	16.333	13.778	15.667
Dividend Growth	-	57.82%	18.55%	-12.06%	2211.40%
Gross Margin	70.94%	78.19%	79.49%	79.69%	76.95%
Operating Margin	57.33%	63.56%	60.21%	60.44%	63.50%
Profit Margin	46.20%	48.39%	43.77%	39.77%	49.36%
Free Cash Flow Margin	19.02%	32.42%	10.88%	11.96%	5.93%
EBITDA	100,048	112,692	89,553	61,451	44,734
EBITDA Margin	70.71%	70.55%	69.84%	73.92%	70.22%
D&A For EBITDA	18,931	11,160	12,345	11,204	4,284
EBIT	81,117	101,532	77,209	50,248	40,450
EBIT Margin	57.33%	63.56%	60.21%	60.44%	63.50%
Effective Tax Rate	26.20%	29.97%	34.62%	36.56%	28.42%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.